Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07300969 · ClinicalTrials.gov registry record · Phase 2

A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression

A Phase 2 study of Major Depressive Disorder (MDD), sponsored by Draig Therapeutics.

Recruiting
Registry status
Phase 2
Development phase
300
Enrollment target
20
Study locations

NCT07300969 is a Phase 2 study of Major Depressive Disorder (MDD) that is actively recruiting participants, run by Draig Therapeutics. The registered enrollment target is 300 participants, above the 145-participant average among 22 other Major Depressive Disorder (MDD) trials with a reported enrollment target (107% higher). The trial reports 20 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07300969, a Phase 2 study of Major Depressive Disorder (MDD), is actively recruiting participants, sponsored by Draig Therapeutics.

RECRUITING
Registry status
Phase 2
Development phase
300 participants
Enrollment target
20
Study locations

Study Summary

The goal of this clinical trial is to learn if DT-101 can treat depression in adults. The effect of DT-101 will be compared to placebo. Subjects will attend the clinic every couple of weeks complete general health checks and complete questionnaires.

Conditions Studied

Major Depressive Disorder (MDD)

Interventions

  • DRUG Placebo
  • DRUG DT-101

Study Locations (20)

California

  • Draig Clinical Site - Oceanside
  • Draig Clinical Site - San Diego
  • Draig Clinical Site - Torrance

Florida

  • Draig Clinical Site - Miami
  • Draig Clinical Site - New Port Richey
  • Draig Clinical Site - Orlando

Texas

  • Draig Clinical Site - Austin
  • Draig Clinical Site - DeSoto
  • Draig Clinical Site - Richardson

Arkansas

  • Draig Clinical Site - Bentonville
  • Draig Clinical Site - Little Rock

Georgia

  • Draig Clinical Site - Atlanta
  • Draig Clinical Site - Decatur

Maryland

  • Draig Clinical Site - Gaithersburg

Massachusetts

  • Draig Clinical Site - Watertown

Mississippi

  • Draig Clinical Site - Flowood

Trial Details

FieldValue
Enrollment Target 300 participants
Start Date 2025-12-16
Est. Completion 2027-08
Phase Phase 2

Sponsor

Draig Therapeutics

2 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07300969

The ClinicalTrials.gov registry entry for NCT07300969 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 145-participant average among 22 other Major Depressive Disorder (MDD) trials with a reported enrollment target (107% higher). The listed sponsor is Draig Therapeutics, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Major Depressive Disorder (MDD) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT07300969 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Florida, Texas.

Frequently Asked Questions

What is clinical trial NCT07300969 about?

NCT07300969 is a clinical study titled "A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression". The goal of this clinical trial is to learn if DT-101 can treat depression in adults. The effect of DT-101 will be compared to placebo. Subjects will attend the clinic every couple of weeks complete general health checks and complete questionnaires.

What is the current status of trial NCT07300969?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 300 participants. The study started on 2025-12-16. Estimated completion is 2027-08.

What conditions does trial NCT07300969 study?

This clinical trial studies the following conditions: Major Depressive Disorder (MDD).

What interventions are being tested in trial NCT07300969?

The interventions under investigation include: Placebo (DRUG), DT-101 (DRUG).

Who is sponsoring clinical trial NCT07300969?

This trial is sponsored by Draig Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07300969 being conducted?

This trial has 20 study locations across Arkansas, California, Florida, Georgia, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Major Depressive Disorder (MDD)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Major Depressive Disorder (MDD)

All registered trials for this condition

Arkansas

All trials with a study site in Arkansas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.